Evaluation of the anti-glycation effect and skin protection effect by a supplement containing brown algae extract powder. (A randomized,Double-blind,Placebo-controlled, Parallel group study)

Evaluation of the anti-glycation effect and skin protection effect by a supplement containing brown algae extract powder. (A randomized,Double-blind,Placebo-controlled, Parallel group study) - Evaluation of the anti-glycation effect and skin protection effect by a supplement containing brown algae extract powder.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000044532

Enrollment

Registered

2021-06-15

Start date

2021-06-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult female

Interventions

once a day for eight weeks Placebo capsule once a day for eight weeks

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Japanese female aged between 20 and 65 at the time of informed consent. 2) Subjects who can come on the designated inspection day and can be inspected. 3) Subjects who can make self-judgment and are voluntarily giving written informed consent. 4) Subjects who have less activity in the sunlight for a long time in dairy life. 5) Subjects who have no history of a thyroid disease.

Exclusion criteria

Exclusion criteria: 1) Subjects who have serious medical history or have history of digestive surgery (except for appendicitis). 2) Subjects who have diseases that affect test and safety. 3) Subjects who consume medicinal product, health food or Food for Specified Health Uses(FOSHU) which may influence the outcome of the study. 4) Subjects who have allergy for test foods. 5) Subjects who have chronic dermatitis or atopic dermatitis. 6) Subjects who hope to be pregnant during the test, or who are pregnant, breastfeeding. 7) Subjects who had participated in other clinical trials within a month or will participate in other clinical trials during this study period. 8) Subjects who are judged as unsuitable for the study by the investigator with other reasons.

Design outcomes

Primary

Measure	Time frame
Blood AGEs(pentosidine) Minimal erythema dose(MED)	—

Secondary

Measure	Time frame
Skin image analysis by VISIA	—

Countries

Japan

Contacts

Public ContactNaoto Takebe

Kaigen Pharma Co.,Ltd. Produce Planning Dept.

n_takebe@kaigen-pharma.co.jp03-5819-2815

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026